Lesley Burgess - Concepedia

Author

Lesley Burgess

Also Known As

Burgess, Lesley, K Coetzee, L Burgess, L J Burgess, L. Burgess, L. J. BURGESS, L. J. Burgess, L.J Burgess, L.J. Burgess, Lesley Burgess

121

Publications

11K

Citations

H-Index

Concepts

All Affiliations

Tygerberg Hospital Stellenbosch University University of Cape Town Université de Montréal University of Toronto

About

Lesley Burgess is an author at Tygerberg Hospital specializing in medicine, cardiovascular disease, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	7K
2	Public Health	5	5	3.1K
3	Arts	1	1	41
4	Education	1	1	41
5	Health Sciences	1	1	82

Lesley Burgess

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Frederick J. Raal, Evan A. Stein, Robert Dufour, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolMedicine	2014	734
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia Dirk Blom, Tomas Hala, Michael A. Bolognese, New England Journal of Medicine	2014	700
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure Milton Packer, John J.V. McMurray, Akshay S. Desai, Circulation	2014	661
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Evinacumab in Patients with Refractory Hypercholesterolemia Robert S. Rosenson, Lesley Burgess, Christoph Ebenbichler, New England Journal of Medicine	2020	283
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy Mary P. McGowan, Jean‐Claude Tardif, R Češka, PLoS ONE	2012	220
Combined Use of Pleural Adenosine Deaminase With Lymphocyte/Neutrophil Ratio Lesley Burgess, Frans Maritz, Irene Le Roux, CHEST Journal InflammationGranulocytePleural Adenosine DeaminaseHematologyImmunology	1996	185
Comparative Analysis of the Biochemical Parameters Used to Distinguish Between Pleural Transudates and Exudates Lesley Burgess, Frans Maritz, J. J. F. Taljaard CHEST Journal Biochemical ParametersPathologyPleural EffusionPleural DiseaseBetween Pleural Transudates	1995	160

Page 1